Table 1.

Analysis of EBV specificity within the patient CTL lines

EBV protein	HLA restriction and epitope sequence	No. of CTL lines, responders/tested (%)
EBNA1	B35: HPV	1/3 (33)
EBNA2	A2: DTP	0/9 (0)
EBNA3A	A2: SVR; A3: RLR; B7: RPP, VPA; B8: QAK, FLR; B35: YPL	4/16 (25)
EBNA3B	A11: AVF, IVT, LPG, DEP, NPT; A24: TYS; B35: AVL; B44: VEI	3/8 (37.5)
EBNA3C	A2: LLD; B27: FRK; B44: EEN	0/13 (0)
LMP2	A2: CLG; A11: SSC; A24: TYG; B27: RRR; B35: MSG	5/17 (29)
BMLF1, BZLF1, BRLF1	A2: GLC, YVL, TLD; A3: RVR, KHS; A11: ATI; A24: DYC; B8: RAK; B35: EPL	13/17 (76)